Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 18,410 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Female Clear all
Completed Not applicable Interventional Results available

Continuous Glucose Monitoring in Patients With End-Stage Kidney Disease and Burnt-Out Diabetes

NCT05741489
View directory record Official record
Conditions
End Stage Kidney Disease
Interventions
Continuous glucose monitoring (CGM)
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 29, 2026, 2:34 PM EDT
Withdrawn Phase 2 Interventional

BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer

NCT00040989
View directory record Official record
Conditions
Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer
Interventions
BAY 56-3722, enzyme inhibitor therapy
Drug · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
26
States / cities
Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 29, 2026, 2:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

External vs Combined Focus Effects on Landing in Female Athletes

NCT07367308
View directory record Official record
Conditions
Valgus Deformity, Not Elsewhere Classified, Knee, Injury, Knee
Interventions
Single-Leg Drop Vertical Jump, Combined Focus of Attention Instruction, External Focus of Attention Instruction, No instruction
Other
Lead sponsor
Bahçeşehir University
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 29, 2026, 2:34 PM EDT
Terminated Phase 3 Interventional

Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer

NCT00016276
View directory record Official record
Conditions
Cardiac Toxicity, Inflammatory Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
Interventions
dexrazoxane hydrochloride, doxorubicin hydrochloride, cyclophosphamide, paclitaxel, trastuzumab, therapeutic conventional surgery, radiation therapy, tamoxifen citrate, laboratory biomarker analysis
Drug · Biological · Procedure + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 29, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment

NCT01082640
View directory record Official record
Conditions
Renal Impairment
Interventions
Febuxostat, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
58
States / cities
Birmingham, Alabama • Peoria, Arizona • Sierra Vista, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2013 · Synced Oct 29, 2026, 2:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners

NCT03112668
View directory record Official record
Conditions
Malignant Female Reproductive System Neoplasm, Malignant Hepatobiliary Neoplasm, Partner, Stage III Breast Cancer, Stage III Cervical Cancer, Stage III Colorectal Cancer, Stage III Lung Cancer, Stage III Prostate Cancer, Stage III Skin Melanoma, Stage III Uterine Corpus Cancer, Stage IIIA Breast Cancer, Stage IIIA Cervical Cancer, Stage IIIA Colorectal Cancer, Stage IIIA Lung Carcinoma, Stage IIIA Skin Melanoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Breast Cancer, Stage IIIB Cervical Cancer, Stage IIIB Colorectal Cancer, Stage IIIB Lung Carcinoma, Stage IIIB Skin Melanoma, Stage IIIB Uterine Corpus Cancer, Stage IIIC Breast Cancer, Stage IIIC Colorectal Cancer, Stage IIIC Skin Melanoma, Stage IIIC Uterine Corpus Cancer, Stage IV Breast Cancer, Stage IV Cervical Cancer, Stage IV Colorectal Cancer, Stage IV Lung Cancer, Stage IV Prostate Cancer, Stage IV Skin Melanoma, Stage IV Uterine Corpus Cancer, Stage IVA Cervical Cancer, Stage IVA Colorectal Cancer, Stage IVA Uterine Corpus Cancer, Stage IVB Cervical Cancer, Stage IVB Colorectal Cancer, Stage IVB Uterine Corpus Cancer
Interventions
Cognitive Behavior Therapy, Quality-of-Life Assessment, Questionnaire Administration, Survey Administration
Behavioral · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 29, 2026, 2:34 PM EDT
Recruiting No phase listed Observational

The Immune System's Response to Young Women's Breast Cancer

NCT01503190
View directory record Official record
Conditions
Breast Cancer, Breast Cancer and Pregnancy
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
5
States / cities
Aurora, Colorado • Denver, Colorado • Highlands Ranch, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 29, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer

NCT03643510
View directory record Official record
Conditions
Adenocarcinoma of Endometrium
Interventions
Fulvestrant, Abemaciclib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 29, 2026, 2:34 PM EDT
Completed Phase 2 Interventional

Self Management in Urinary Catheter Users

NCT00883220
View directory record Official record
Conditions
Urinary Retention, Neurogenic Bladder
Interventions
Self-management of urinary catheter
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Oct 29, 2026, 2:34 PM EDT
Recruiting Phase 2 Interventional

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

NCT05941520
View directory record Official record
Conditions
Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions
Acolbifene Hydrochloride, Biospecimen Collection, Mammography, Questionnaire Administration, Random Periareolar Fine-Needle Aspiration, Tamoxifen
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
35 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Duarte, California • Chicago, Illinois • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 29, 2026, 2:34 PM EDT
Completed Not applicable Interventional Results available

InterStim Basic Evaluation Lead Post-Market Clinical Follow-up Study

NCT04016324
View directory record Official record
Conditions
Overactive Bladder, Urinary Urge Incontinence, Urgency-frequency Syndrome
Interventions
InterStim Basic Evaluation lead and foramen needle
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
10
States / cities
St. Petersburg, Florida • Tampa, Florida • Plymouth, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 29, 2026, 2:34 PM EDT
Completed No phase listed Observational Results available

Ease of Use and Blood Clotting for the Gambro Polyflux HD-C4 Big Dialyzer

NCT00659724
View directory record Official record
Conditions
Chronic Kidney Failure
Interventions
Not listed
Lead sponsor
Vantive Health LLC
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Easton, Maryland • Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 29, 2026, 2:34 PM EDT
Withdrawn Phase 4 Interventional

Acthar on Proteinuria in IgA Nephropathy Patients

NCT02382523
View directory record Official record
Conditions
IgA Nephropathy, Proteinuria
Interventions
Acthar 80 unit injection
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 29, 2026, 2:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study That Evaluates the Effect of CYP3A4 Inhibition on Lu AG06466 in Healthy Men and Women

NCT04405323
View directory record Official record
Conditions
Healthy
Interventions
Lu AG06466, Itraconazole
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 14, 2020 · Synced Oct 29, 2026, 2:34 PM EDT
Completed Phase 3 Interventional

Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer

NCT00006459
View directory record Official record
Conditions
Breast Cancer
Interventions
gemcitabine hydrochloride, paclitaxel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
31
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Fountain Valley, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Oct 29, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer

NCT00309959
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma
Interventions
Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
26
States / cities
Aurora, Colorado • Chicago, Illinois • Urbana, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 29, 2026, 2:34 PM EDT
Recruiting Phase 4 Interventional

AtorvaStatin Postpartum and Reduction of Cardiovascular risK

NCT06632379
View directory record Official record
Conditions
Hypertensive Disorders of Pregnancy, Preeclampsia, Gestational Hypertension
Interventions
Atorvastatin 10 mg, Placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
20 Years to 50 Years · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 29, 2026, 2:34 PM EDT
Completed No phase listed Observational

QStat Cartridge in Obstetric Patients

NCT06255496
View directory record Official record
Conditions
Blood Loss Massive, Post Partum Hemorrhage
Interventions
Quantra Hemostasis Analyzer with the QStat Cartridge
Diagnostic Test
Lead sponsor
HemoSonics LLC
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
6
States / cities
Rochester, New York • Columbus, Ohio • Oklahoma City, Oklahoma + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 29, 2026, 2:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Diet on Pregnancy Outcome and Child Obesity

NCT03232762
View directory record Official record
Conditions
Pregnancy Related, Diet Modification, Obesity, Hypertension, Pre-Eclampsia, Blood Pressure, Breast Feeding, Birth Weight
Interventions
Refined Grains, Whole Grains
Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 29, 2026, 2:34 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Comparison of Two Different Diets on Health Outcomes

NCT00269646
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
Low-carbohydrate and high-carbohydrate diets
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 64 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 18, 2009 · Synced Oct 29, 2026, 2:34 PM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

C-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United States

NCT07520188
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), Cervical Cancer, Cervical Precancer
Interventions
Qualitative interviews, Focus groups
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
25 Years and older
Enrollment
3,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 29, 2026, 2:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Population-Based Patient-Centric Care: Comprehensive Preventive Cancer Screening Using Health IT

NCT01372527
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Cervical Cancer
Interventions
TopCare: Use of provider knowledge vs. automated system
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 75 Years
Enrollment
103,870 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 3, 2014 · Synced Oct 29, 2026, 2:34 PM EDT
Terminated Phase 2 Interventional

Use of Rosiglitazone in the Treatment of Endometriosis

NCT00115661
View directory record Official record
Conditions
Endometriosis
Interventions
Rosiglitazone
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 17, 2012 · Synced Oct 29, 2026, 2:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis

NCT01340586
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 11, 2016 · Synced Oct 29, 2026, 2:34 PM EDT